Private Trust Company’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $100K | Buy |
191
+27
| +16% | +$14.2K | 0.01% | 955 |
|
2025
Q1 | $104K | Buy |
164
+19
| +13% | +$12.1K | 0.01% | 933 |
|
2024
Q4 | $103K | Sell |
145
-77
| -35% | -$54.8K | 0.01% | 912 |
|
2024
Q3 | $233K | Sell |
222
-50
| -18% | -$52.6K | 0.02% | 642 |
|
2024
Q2 | $286K | Sell |
272
-14
| -5% | -$14.7K | 0.03% | 538 |
|
2024
Q1 | $275K | Buy |
286
+36
| +14% | +$34.7K | 0.03% | 533 |
|
2023
Q4 | $220K | Sell |
250
-153
| -38% | -$134K | 0.03% | 578 |
|
2023
Q3 | $332K | Buy |
403
+94
| +30% | +$77.4K | 0.04% | 425 |
|
2023
Q2 | $222K | Buy |
309
+154
| +99% | +$111K | 0.03% | 529 |
|
2023
Q1 | $127K | Buy |
155
+44
| +40% | +$36.2K | 0.02% | 686 |
|
2022
Q4 | $80K | Sell |
111
-4
| -3% | -$2.88K | 0.01% | 811 |
|
2022
Q3 | $79K | Sell |
115
-3
| -3% | -$2.06K | 0.01% | 750 |
|
2022
Q2 | $70K | Sell |
118
-1,595
| -93% | -$946K | 0.01% | 817 |
|
2022
Q1 | $1.2M | Sell |
1,713
-303
| -15% | -$212K | 0.19% | 138 |
|
2021
Q4 | $1.27M | Sell |
2,016
-132
| -6% | -$83.4K | 0.18% | 141 |
|
2021
Q3 | $1.3M | Buy |
2,148
+96
| +5% | +$58.1K | 0.19% | 132 |
|
2021
Q2 | $1.15M | Buy |
2,052
+231
| +13% | +$129K | 0.17% | 144 |
|
2021
Q1 | $861K | Buy |
1,821
+1,002
| +122% | +$474K | 0.14% | 174 |
|
2020
Q4 | $395K | Buy |
819
+269
| +49% | +$130K | 0.07% | 276 |
|
2020
Q3 | $307K | Sell |
550
-12
| -2% | -$6.7K | 0.06% | 288 |
|
2020
Q2 | $349K | Buy |
+562
| New | +$349K | 0.07% | 262 |
|
2014
Q4 | – | Sell |
-405
| Closed | -$146K | – | 979 |
|
2014
Q3 | $146K | Buy |
405
+15
| +4% | +$5.41K | 0.05% | 321 |
|
2014
Q2 | $110K | Hold |
390
| – | – | 0.04% | 389 |
|
2014
Q1 | $117K | Buy |
390
+200
| +105% | +$60K | 0.04% | 326 |
|
2013
Q4 | $52K | Buy |
190
+184
| +3,067% | +$50.4K | 0.02% | 449 |
|
2013
Q3 | $2K | Sell |
6
-84
| -93% | -$28K | ﹤0.01% | 1442 |
|
2013
Q2 | $20K | Buy |
+90
| New | +$20K | 0.01% | 629 |
|